Cell-based therapeutic strategies for multiple sclerosis
Open Access
- 21 July 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Brain
- Vol. 140 (11), 2776-2796
- https://doi.org/10.1093/brain/awx154
Abstract
The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. However, all are only partially effective in preventing inflammatory tissue damage in the central nervous system and none directly promotes repair. Cell-based therapies, including immunoablation followed by autologous haematopoietic stem cell transplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of endogenous stem cells to enhance their reparative capabilities, and transplantation of oligodendrocyte progenitor cells, have generated substantial interest as novel therapeutic strategies for immune modulation, neuroprotection, or repair of the damaged central nervous system in multiple sclerosis. Each approach has potential advantages but also safety concerns and unresolved questions. Moreover, clinical trials of cell-based therapies present several unique methodological and ethical issues. We summarize here the status of cell-based therapies to treat multiple sclerosis and make consensus recommendations for future research and clinical trials.Funding Information
- European Committee for Treatment and Research in Multiple Sclerosis
This publication has 133 references indexed in Scilit:
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicineExperimental & Molecular Medicine, 2013
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyThe Lancet Neurology, 2012
- Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of InflammationMolecular Therapy, 2012
- CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cellsNature Biotechnology, 2011
- Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cellsNature, 2011
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Mesenchymal and haematopoietic stem cells form a unique bone marrow nicheNature, 2010
- Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosisGlia, 2009
- Neonatal Chimerization with Human Glial Progenitor Cells Can Both Remyelinate and Rescue the Otherwise Lethally Hypomyelinated Shiverer MouseCell Stem Cell, 2008